Johnson & Johnson’s Hematology Portfolio: Breakthroughs to Watch
Johnson & Johnson showcased a robust hematology pipeline at the ASH 2025 meeting, unveiling more than 60 new abstracts. The company highlighted real‑world evidence from thousands of patients, underscoring the efficacy of its CAR‑T, bispecific and gene‑editing therapies. Notably, the MajesTEC‑3 trial delivered encouraging multiple myeloma data, positioning J&J for pivotal readouts in 2026. Executive leadership signaled continued investment in next‑generation blood‑cancer treatments.
Using AI In Patent Practice: Practical and Ethical Issues
At the BIO International Convention’s IP Counsels Committee panel, experts outlined how AI is reshaping patent practice. They classified tools into traditional, generative, and patent‑specific solutions, stressing secure enterprise versions for confidential data. Ethical pitfalls—including AI hallucinations and potential public...
Stelios Papadopoulos Brings the Long View on Biotech on The BioCentury Show
Stelios Papadopoulos, former Biogen chair and current Exelixis leader, warned that biotech faces heightened pricing pressure and rising competition from China despite a surge of over $3 billion in capital in a single day. He argued that the sector can no...
How Alphamab Is Differentiating in Crowded Cancer Targets
Alphamab is launching a next‑generation bispecific antibody‑drug conjugate (ADC) platform that simultaneously engages two tumor antigens while employing a lower drug‑to‑antibody ratio (DAR). The company argues that this design improves the therapeutic index by delivering potent payloads more selectively and...
Third Rock Backs Steve Paul’s Latest Schizophrenia Spinout in $165M Round: Venture Report
Third Rock Ventures led a $165 million financing round for Steve Paul’s newest schizophrenia‑focused biotech, marking a significant venture capital commitment to neuropsychiatric innovation. Paul, a serial biotech founder, will use the capital to move novel mechanisms from discovery into early...
Early Signals Stack Up: Two Small Molecules Activate GCase in Parkinson’s
Gain Therapeutics reported Phase Ib data showing that its small‑molecule program reduces glucosylceramide substrate in the central nervous system, confirming target engagement of glucocerebrosidase (GCase). In parallel, Vanqua Bio presented early evidence that its distinct compound activates peripheral GCase while...
Induced Pluripotent Stem Cells: From Dish to Freezer and Back
Kobe University researchers have devised a cryopreservation protocol that freezes induced pluripotent stem cells (iPSCs) directly in their 2‑dimensional culture dishes. The method uses the inexpensive amino acid D‑proline combined with a synthetic polymer and a brief enzymatic step to...
Spray-On Antibacterial Coating Offers New Protection for Plants Against Disease and Drought
UC San Diego engineers have created a water‑based spray polymer coating that shields plant leaves from bacterial infection and improves drought tolerance. The polynorbornene polymer carries positive charges that disrupt bacterial membranes while remaining gas‑permeable for normal leaf respiration. Laboratory...
Researchers Co-Develop New Deep Learning Platform to Advance Precision Medicine
Researchers from Marshall University and the University of Missouri unveiled G2PDeep, a web‑based deep‑learning platform that fuses six major omics data streams to predict complex health outcomes. The peer‑reviewed study in *Biomolecules* demonstrates the tool’s ability to identify molecular markers,...
The Antibiotic Delafloxacin Emerges as a Potential Therapeutic Alternative Against Legionella
Researchers at the IGTP demonstrated that delafloxacin inhibits intracellular Legionella replication more effectively than levofloxacin in a macrophage model. The fluoroquinolone achieved bacterial killing at concentrations five to ten times lower than the current standard, except for L. longbeachae where...
New Role for Tam Man Hong at Xtalpi
Xtalpi announced that veteran biotech executive Tam Man Hong will assume the role of President, Business Development, effective immediately. The appointment comes as the company finalizes a $150 million Series B financing round to expand its AI‑driven protein therapeutics platform. Hong, who...
Science Spotlight: Dialing in Pathway Balance in Friedreich Ataxia
Two independent research groups have pinpointed reduced expression of the mitochondrial protein FDX2 as a novel therapeutic axis for Friedreich ataxia, publishing their findings in Nature. The studies argue that frataxin (FXN) and FDX2 function as a stoichiometric pair, and...
Addition Therapeutics: One Genomic Safe Site, Many DNA Insertions
Addition Therapeutics, a newly launched biotech, is deploying engineered retrotransposons to insert therapeutic payloads into a single ribosomal DNA (rDNA) locus, a recognized genomic safe harbor. By concentrating multiple genes at this highly transcribed, repetitive site, the platform promises stable...
Eight of the Biggest Immunology and Inflammation (I&I) Deals in 2025
In 2025 the immunology and inflammation sector saw eight blockbuster partnerships, each worth between $1.7 billion and $4 billion. Deals ranged from AstraZeneca’s $175 million upfront, $4.4 billion‑potential collaboration with Harbour BioMed to Vor Bio’s surprising $4 billion licensing of telitacicept despite a massive wind‑down....
Accelerating Drug Combination Discovery with Machine Learning
St. Jude researchers unveiled Combocat, an open‑source platform that merges acoustic liquid handling with machine‑learning models to screen drug combinations at unprecedented scale. The system tested 9,045 drug pairs on a neuroblastoma cell line, identifying multiple synergistic hits that were...
BIO IP Conference Looks at Academics and Perceptions of IP
The BIO IP Counsel Committee Conference addressed growing skepticism toward patents in biopharma, amplified by pandemic‑era messaging that frames IP as a barrier to care. Panelists argued that patents remain vital incentives for costly research and development, despite public concerns...
Patient Advocates Urge Action on PPRV to Help Fight Rare Disease
Patient advocates at BIO’s December Coffee Chat urged Congress to reauthorize the Pediatric Priority Review Voucher (PPRV) program before year‑end. The voucher scheme, which expired in 2024, has awarded 63 vouchers for 47 rare pediatric diseases, turning four treated conditions...
RTW Leans Into NewCo Model with GenSci Deal for Ocular Autoimmune Therapy: Deals Report
RTW Therapeutics announced a strategic partnership with GenSci to form a new joint‑venture focused on developing an ocular autoimmune therapy. The collaboration adopts a NewCo model, with both parties contributing capital and expertise to accelerate drug discovery for non‑infectious uveitis....
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
Sanofi’s Bruton’s tyrosine kinase (BTK) inhibitor failed to meet its primary endpoint in a pivotal trial for primary progressive multiple sclerosis, while the company awaits an FDA decision on a secondary progressive indication. Roche, meanwhile, reported encouraging efficacy and safety...
Measuring Drug Target Success
The episode explores how drug targets are identified and validated, highlighting genetic, animal, and in‑vitro evidence as key sources. It discusses the limited predictive power of pre‑clinical data, noting that genetically validated targets double the odds of clinical success while...
$12B-Plus in New Life Sciences Funds This Year
Venture capital activity in life sciences has surged in 2025, with at least 27 firms announcing new funds. Collectively, these vehicles have attracted more than $12 billion in capital, marking a record inflow for the sector. Notably, four of the funds...
Who Invented What? BIO IP Panel Tackles Joint Inventorship
The BIO IP panel highlighted that joint inventorship is now the norm in biotech, replacing the lone‑inventor myth. It outlined the legal elements—conception, collaboration, corroboration—and illustrated them with real and hypothetical cases, including AI‑driven research. Panelists warned that mis‑attributing inventors...
VIDO – Five Ways Our Research Strengthened Animal Health in 2025
In 2025 the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) tackled five critical animal‑health challenges, from a first‑record H5N1 outbreak in dairy cattle to a world‑first chlamydia vaccine for endangered koalas. Researchers demonstrated natural immunity in infected cows,...
Biotech in 2025: A Retrospective
2025 marked a phase shift in biotech as metabolic health, AI, and radiopharmaceuticals moved from hype to mainstream impact. GLP‑1 and related incretin drugs expanded into broader cardiometabolic indications, with over 40 candidates in development and major licensing deals reshaping...
Lisbon Is Calling: The BIO-Europe Startup Spotlight Returns in March 2026
BIO‑Europe’s Startup Spotlight, the premier European biopharma pitch competition, announced its 2025 champion, German spin‑out Fusix Biotech, which secured the trophy in Vienna with its InFUSE chimeric oncolytic virus platform. The contest selects eight early‑stage companies—fewer than 25 employees and...
Elkedonia: Antidepressants that Act Downstream of Neurotransmitters
Elkedonia, a seed‑funded French biotech, is developing a novel class of antidepressants that target the transcription factor ELK1 to reboot neuroplasticity downstream of classic neurotransmitter pathways. The company announced a €5 million seed round led by European venture partners and presented...
Obesity Data, Kymera and FDA Sentiment Survey Results — a BioCentury Podcast
Obesity therapeutics dominated the latest BioCentury podcast, with Eli Lilly unveiling new top‑line data for its triple‑agonist retatrutide, positioning it as a best‑in‑class weight‑loss candidate. Structure Therapeutics reported strong Phase IIb results for its oral GLP‑1, reigniting interest in non‑injectable options, while...
Pursuing a Rare Autoimmune Disease Accelerated Kyverna’s Path to BLA
Kyverna Therapeutics announced that its lead autoimmune CAR‑T, mivocabtagene autoleucel (miv‑cel), achieved both primary and secondary endpoints in a registrational Phase II trial for stiff person syndrome. The data positions the therapy as the first autoimmune CAR‑T to pursue a Biologics...
MHRA Deepens Global Strategy with Singapore Regulatory Pathway
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a regulatory innovation corridor with Singapore’s Health Sciences Authority, offering companies coordinated scientific advice from both regulators. Flagship Pioneering is the first industry partner, giving its biotech portfolio a...
The Busiest Biotech Seed and Series A Investors of 2025
In 2025 more than a dozen venture capital firms have each disclosed at least five seed or Series A biotech investments, making them the busiest early‑stage investors of the year. BioCentury’s data shows that capital is flowing into a wide range...
Keep an Eye on These 15 Biotech Companies in 2026
Labiotech’s 2026 "biotechs to watch" list spotlights fifteen companies across gene therapy, cell therapy, base editing, radiopharma and metabolic disease, each with pivotal clinical or regulatory milestones slated for the coming year. Highlights include AAVantgarde’s $141 million Series B and proof‑of‑concept trials...
Bayh-Dole at 45: Still an Engine for Innovation
The Bayh‑Dole Act, celebrating its 45th anniversary, has turned federally funded university research into a powerhouse of commercial innovation. Between 1996 and 2020 it generated up to $1.9 trillion in economic output, created 6.5 million jobs and spurred 19,000 startups, resulting in...
CEO Moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression
BioCentury reports a wave of CEO appointments across five life‑science firms. Prolynx named a former biotech COO to steer its next growth phase, while Centessa tapped a veteran pharma executive to accelerate its pipeline expansion. Kyowa Kirin promoted its internal R&D...
Makary’s Embrace of Ideology, Conspiracies Puts FDA at Risk: A Perspective
FDA Commissioner Marty Makary is openly endorsing debunked conspiracy theories while linking drug approvals to political pricing deals and onshoring incentives. His recent podcast remarks claimed Lyme disease and AIDS originated from government labs, blurring the line between science and...
EMA’s CHMP Backs New Medicines From Hansoh, Cytokinetics
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for five new drugs and vaccines in its December meeting. Two products originate from Chinese biotech Hansoh, while three are from U.S. firm Cytokinetics. The...
BeOne Strengthens Its BTK Position at ASH
BeOne Medicines presented six‑year follow‑up data for its BTK inhibitor Brukinsa (zanubrutinib) at the ASH meeting, showing roughly 75% of treatment‑naïve chronic lymphocytic leukemia (CLL) patients remain progression‑free. The company also shared early results from a novel BTK degrader that...
House Passes BIO-Backed Legislation to Increase Access to Capital
The U.S. House of Representatives approved the Incentivizing New Ventures and Economic Strength Through Capital Formation (INVEST) Act on Dec. 11, passing it 302‑123 with bipartisan support. The legislation, championed by BIO, aims to remove regulatory hurdles and expand capital access...
Fifteen Gift Ideas for a Biotech Enthusiast This Holiday Season
The article curates fifteen holiday gift ideas tailored for biotechnology enthusiasts, ranging from playful items like the Viral board game to advanced tools such as portable DNA sequencers. It highlights novelty products—including glow‑in‑the‑dark mushrooms, DNA‑shaped cookie cutters, and personalized DNA...
Tackling Pulmonary Fibrosis: Boehringer Ingelheim’s New Drug + AI Approach
Boehringer Ingelheim has launched the first new pulmonary‑fibrosis medicine in more than a decade, an oral PDE4B inhibitor that secured FDA approval and will be rolled out globally. The company also introduced eLung, an AI‑driven imaging tool that spots microscopic...
Lilly’s Triple Agonist Contender for Best-in-Class Weight Loss
Eli Lilly announced Phase III TRIUMPH-4 data for its triple‑agonist retatrutide, showing a 26.6% placebo‑adjusted weight loss after 68 weeks at the 12 mg weekly dose. The study enrolled 445 obese adults with knee osteoarthritis, and the highest dose translated to...
BioCentury’s FDA Survey Reflects an Industry in Distress
BioCentury’s 2025 FDA survey paints a picture of deep distress across biopharma, flagging “inconsistency” as the sector’s most pressing worry. Respondents praised FDA staff effort but argued senior leadership decisions appear driven by political agendas rather than science. The perceived...
Front Row with BioCentury: Inside the Turbulent Ride of Cell and Gene Therapy
Cell and gene therapy continues to attract attention despite a recent wave of setbacks that have slowed commercial momentum. Manufacturing complexities, heightened regulatory scrutiny, and pricing debates are creating a turbulent environment for developers. Nevertheless, breakthrough scientific data and expanding...
Science Spotlight: Chinese Researchers Advance PROTAC Design
Chinese scientists have unveiled a next‑generation PROTAC scaffold that delivers oral bioavailability and heightened target selectivity. The platform successfully degrades previously undruggable proteins, including KRAS(G12C), and demonstrates tumor‑growth inhibition in mouse models. By integrating AI‑guided linker optimization, the researchers mitigated...
Charlotte Emerging as a Global Leader in Health Care Innovation and Med Tech
Charlotte, long known as a U.S. financial hub, has launched The Pearl—a $75 million health‑care innovation district—in midtown in June 2025. The campus brings together IRCAD North America, Wake Forest University School of Medicine, global med‑tech firms, startup labs, and an AI‑driven clinical‑trial...
